CAMBRIDGE, England & EDINBURGH, Scotland--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, ...
CAMBRIDGE, England--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that ...
Axol Bioscience’s CiPA-validated ventricular cardiomyocytes can be used as a robust cardiotoxicity measurement tool. Axol Bioscience, a provider of induced pluripotent stem cell (ISPC)-derived cells, ...
Axol Bioscience Ltd. (Axol), a leading pluripotent stem cell technology provider for drug discovery has signed an exclusive agreement with StrataStem to access and commercialize its extensive ...
Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ Companies will incorporate cells and technology to create a ‘clinical trial in a dish’ Axol Bioscience – a stem ...
Sygnature Discovery, a world-leading integrated drug discovery provider and non-clinical solutions provider, has announced a scientific collaboration with human induced pluripotent stem cell (iPSC) ...
The private equity funding will enable the startup biotech firm to expand product development as well as sales and marketing capabilities. On August 15, 2017, Calculus Capital (London), a private ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback